mitomycin has been researched along with Fatigue in 6 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Newer radiation techniques, and the application of continuous 5-FU exposure during radiation therapy using oral capecitabine may improve the treatment of anal cancer." | 5.17 | Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. ( Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Dewit, L; Schellens, JH, 2013) |
| " We screened cancer patients' tumors for FA functional defects then aimed to establish the safety/feasibility of administering PARP inhibitors as monotherapy and combined with a DNA-breaking agent." | 2.82 | Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. ( Bekaii-Saab, T; Chen, A; Duan, W; Ji, J; Lustberg, M; Marshall, J; Rose, J; Schaaf, LJ; Shilo, K; Thurmond, J; Timmers, C; Villalona-Calero, MA; Westman, JA; Xiaobai, L; Zhao, W, 2016) |
| "Mitomycin C (MMC) has potent cytotoxicity but cumulative toxicity limits widespread use." | 2.80 | Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. ( Amitay, Y; Berger, R; Gabizon, AA; Golan, T; Grenader, T; La-Beck, NM; Ohana, P; Shmeeda, H; Tahover, E, 2015) |
| "Although fatigue was the most frequently encountered toxicity safety profiles were generally predictable and manageable." | 2.73 | Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. ( Cho, EK; Chung, M; Hong, J; Kim, YS; Lee, JH; Lee, WK; Nam, E; Park, J; Park, SH; Shin, DB, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Siracusano, S | 1 |
| Silvestri, T | 1 |
| Bassi, S | 1 |
| Porcaro, AB | 1 |
| Cerruto, MA | 1 |
| Talamini, R | 1 |
| Artibani, W | 1 |
| Deenen, MJ | 1 |
| Dewit, L | 1 |
| Boot, H | 1 |
| Beijnen, JH | 1 |
| Schellens, JH | 1 |
| Cats, A | 1 |
| Golan, T | 1 |
| Grenader, T | 1 |
| Ohana, P | 1 |
| Amitay, Y | 1 |
| Shmeeda, H | 1 |
| La-Beck, NM | 1 |
| Tahover, E | 1 |
| Berger, R | 1 |
| Gabizon, AA | 1 |
| Villalona-Calero, MA | 1 |
| Duan, W | 1 |
| Zhao, W | 1 |
| Shilo, K | 1 |
| Schaaf, LJ | 1 |
| Thurmond, J | 1 |
| Westman, JA | 1 |
| Marshall, J | 1 |
| Xiaobai, L | 1 |
| Ji, J | 1 |
| Rose, J | 1 |
| Lustberg, M | 1 |
| Bekaii-Saab, T | 1 |
| Chen, A | 1 |
| Timmers, C | 1 |
| Park, SH | 1 |
| Kim, YS | 1 |
| Hong, J | 1 |
| Park, J | 1 |
| Nam, E | 1 |
| Cho, EK | 1 |
| Shin, DB | 1 |
| Lee, JH | 1 |
| Lee, WK | 1 |
| Chung, M | 1 |
| Sanz-Altamira, PM | 1 |
| Spence, LD | 1 |
| Huberman, MS | 1 |
| Posner, MR | 1 |
| Steele, G | 1 |
| Perry, LJ | 1 |
| Stuart, KE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent C[NCT04085250] | Phase 2 | 264 participants (Actual) | Interventional | 2019-11-28 | Active, not recruiting | ||
| An Open Phase 1B Study for Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Oxaliplatin-based Chemotherapy in Patients With Gastro-intestinal Malignancies[NCT04729205] | Phase 1 | 9 participants (Actual) | Interventional | 2021-01-13 | Terminated (stopped due to Investigational drug not available) | ||
| A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.[NCT01705002] | Phase 1 | 88 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for mitomycin and Fatigue
| Article | Year |
|---|---|
Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; C | 2013 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; | 2016 |
Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study.
Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; | 2008 |
Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial.
Topics: Abdominal Pain; Adult; Aged; Alkaline Phosphatase; Angiography; Antimetabolites, Antineoplastic; Ant | 1997 |
1 other study available for mitomycin and Fatigue
| Article | Year |
|---|---|
Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Age Factors; Aged; Aged, 80 and over; A | 2018 |